Sage Journals: Discover world-class research

Abstract

Palmoplantar psoriasis is a chronic disabling condition characterized by erythematous scaly plaques of the palms and soles, often with associated pain, erythema, and fissuring. It is thought to occur in up to 40% of psoriasis patients, and can at times be the sole manifestation of disease. This condition poses a unique therapeutic challenge in that it is refractory to many therapies currently approved for the management of psoriasis. Recently, apremilast, a phosphodiesterase-4 inhibitor, became the first small molecule approved for the management of psoriasis and psoriatic arthritis. While showing promising results in plaque psoriasis, this therapy has yet to be fully evaluated for the management of palmoplantar psoriasis. Herein, we report a case of successful clearance of severe recalcitrant palmoplantar psoriasis using a novel combination of acitretin and apremilast.

Keywords

palmoplantar psoriasis psoriasis apremilast acitretin retinoids PDE4 inhibitor

Get full access to this article

View all access options for this article.

References

Farber

E.M.

Nail

M.L.

. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974; 148: 1–18.

Kumar

Saraswat

Kaur

. Palmoplantar lesions in psoriasis a study of 3065 patients. Acta Derm Venereol. 2002; 82: 192–5.

Richetta

A.G.

Mattozzi

Giancristoforo

Safety and efficacy of adalimumab in the treatment of moderate to severe palmoplantar psoriasis: an open label study.

Clin Ter. 2012; 163(2): e61–6.

Di Lernia

Guareschi

. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J. 2010; 16: 8.

S.C.

Goldminz

A.M.

Kim

Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.

J Dermatolog Treat. 2013 Jun; 24(3): 179–87.

Marsaland

A.M.

Chalmers

R.J.

Hollis

Interventions for chronic palmoplantar pustulosis.

Cochrane Database Syst Rev 2006. Jan 25;(1): CD001433.

Spuls

P.I.

Hadi

Rivera

Retrospective analysis of the treatment of psoriasis of the palms and soles.

J Dermatolog Treat. 2003; 14 Suppl 2: 21–5.

Mehta

B.H.

Amladi

S.T.

. Evaluation of topical 0.1% Tazarotene cream in the treatment of palpoplantar psoriasis: An observer-blinded randomized controlled study. Indian J Dermatol. 2011 Jan-Feb; 56(1): 40–43.

Frankel

A.J.

. Goldenberg G. Insights into Treating Palmoplantar Psoriasis. The Dermatologist. Volume 18 - Issue 8 - August 2010.

10.

Lozinski

Barzilai

Pavlotsky

. Broad-band UVB versus paint PUVA for palmoplantar psoriasis treatment. J Dermatolog Treat 2015 Oct 20: 1–3.

11.

Neumann

N.J.

Mahnke

Korpusik

Treatment of Palmoplantar Psoriasis with monochromatic excimer light (308-nm) versus cream PUVA.

Acta Derm Venereol. 2006; 86: 22–4.

12.

Ettler

Richards

. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol. 2001; 40: 541–2.

13.

Weinberg

J.M.

. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003; 72: 396–8.

14.

Kasche

Pfab

Hein

Severe psoriasis pustulosa palmaris et plantaris (Barber-Königsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept).

J Eur Acad Dermatol Venereol. 2007; 21: 255–7.

15.

Bissonnette

Nigen

Langley

R.G.

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmoplantar (PP) pustular psoriasis of PP pustulosis; results from a randomized controlled trial.

J Eur Acad Dermatol Venereol. 2014 Oct; 28(10): 1298–305.

16.

Bissonnette

Poulin

Bolduc

Etanercept in the treatment of palmoplantar pustulosis. Innovaderm Research, Montreal, QC, Canada.

J Drugs Dermatol. 2008 Oct; 7(10): 940–6.

17.

Cullen

Kroshinsky

Cheifetz

A.S.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

Aliment Pharmacol Ther. 2011; 34: 1318–27.

18.

Chaplin

Dunnill

. Otezla for plaque psoriasis and psoriatic arthritis. Prescriber. 26.13–16 (2015): 33–35.

19.

Boudry . Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis. Switzerland - Business Wire (2014).

20.

Papp

Reich

Leonardi

C.L.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

J Am Acad Dermatol. 2015 Jul; 73(1): 37–49.

Successful Treatment of Palmoplantar Psoriasis Using Combination Acitretin and Apremilast: A Case Report

Abstract

Keywords

Get full access to this article

References